Published in Mol Immunol on July 01, 1991
Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen. J Virol (1993) 1.02
Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein. Clin Exp Immunol (1993) 0.99
An intramolecular disulfide bridge between Cys-7 and Cys61 determines the structure of the secretory core gene product (e antigen) of hepatitis B virus. J Virol (1993) 0.95
Inhibition of alpha interferon signaling by hepatitis B virus. J Virol (2006) 0.95
A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci U S A (1993) 0.91
Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens. J Virol (1997) 0.83
Predominance of precore mutations and clinical significance of basal core promoter mutations in chronic hepatitis B virus infection in Indonesia. Biomed Rep (2013) 0.83
Relevance of cysteine residues for biosynthesis and antigenicity of human hepatitis B virus e protein. J Virol (1993) 0.80
A recombinant multiepitope protein for hepatitis B diagnosis. Biomed Res Int (2013) 0.77
Mutations in hepatitis B virus core regions correlate with hepatocellular injury in Chinese patients with chronic hepatitis B. World J Gastroenterol (2005) 0.75
New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol (1972) 6.33
Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology (1994) 4.77
Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 2.74
Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol (1993) 2.50
Demonstration of an octasaccharide repeating unit in the extracellular polysaccharide of Rhizobium meliloti by sequential degradation. J Am Chem Soc (1977) 2.48
Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol (1989) 2.27
Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol (1992) 2.14
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06
Transmission of hepatitis B virus by HBV-negative blood transfusion. Lancet (1995) 2.06
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol (1992) 1.94
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80
An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods (1981) 1.80
A new antigen-antibody system. Clinical significance in long-term carriers of hepatitis B surface antigen. JAMA (1975) 1.78
Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77
Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett (1991) 1.73
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol (1989) 1.61
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1992) 1.57
Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis (1990) 1.54
Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections. J Clin Microbiol (1984) 1.53
Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol (1987) 1.52
Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology (1980) 1.50
Homotypic echoviruses share aminoterminal VP1 sequence homology applicable for typing. J Med Virol (2001) 1.50
Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG (2000) 1.47
Hepatitis B virus capsid: localization of the putative immunodominant loop (residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens. J Mol Biol (1998) 1.44
Sequence variation within three important cytomegalovirus gene regions in isolates from four different patient populations. J Clin Microbiol (1998) 1.43
Dynamic changes in HIV-1 quasispecies from azidothymidine (AZT)-treated patients. FASEB J (1992) 1.41
Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J Virol (1992) 1.39
Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol (1992) 1.37
Complete sequencing of a gibbon hepatitis B virus genome reveals a unique genotype distantly related to the chimpanzee hepatitis B virus. Virology (1996) 1.34
Genotype F prevails in HBV infected patients of hispanic origin in Central America and may carry the precore stop mutant. J Med Virol (1997) 1.33
Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta (1982) 1.33
Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol (1993) 1.32
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother (1986) 1.31
Diagnosis of infectious mononucleosis by the monospot test. Am J Clin Pathol (1969) 1.28
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
A new antigen complex co-occurring with Australia antigen. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.27
Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen. J Med Virol (1991) 1.26
Contrasting roles of rivers and wells as sources of drinking water on attack and fatality rates in a hepatitis E epidemic in Somalia. Am J Trop Med Hyg (1994) 1.26
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother (1987) 1.25
Variations in the cytomegalovirus major immediate-early gene found by direct genomic sequencing. J Clin Microbiol (1992) 1.22
Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis (1986) 1.22
A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol (1990) 1.21
IgG antibodies to human herpesvirus-6 in children and adults and in primary Epstein-Barr virus infections and cytomegalovirus infections [corrected]. J Virol Methods (1988) 1.20
Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis (1992) 1.20
A novel method for determining the sensitivity of herpes simplex virus to antiviral compounds. J Virol Methods (1983) 1.19
A new peptide for human parvovirus B19 antibody detection. Scand J Infect Dis (1989) 1.19
Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol (2000) 1.18
Cytomegalovirus DNA detection of an immediate early protein gene with nested primer oligonucleotides. J Virol Methods (1991) 1.18
Characterization of a new antigen-antibody system associated with hepatitis B. Clin Exp Immunol (1975) 1.18
Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med (1986) 1.18
Molecular epidemiology of hepatitis B virus in Central America reflected in the genetic variability of the small S gene. J Infect Dis (1997) 1.17
IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol (1988) 1.16
Inhibition of cytomegalovirus late antigens by phosphonoformate. Intervirology (1980) 1.15
Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol (2001) 1.15
Identification of hepatitis B virus core protein regions exposed or internalized at the surface of HBcAg particles by scanning with monoclonal antibodies. Virology (1994) 1.14
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrob Agents Chemother (1989) 1.13
Immunodominant regions within the hepatitis C virus core and putative matrix proteins. J Clin Microbiol (1992) 1.12
Comparison of class and subclass distribution of antibodies to the hepatitis B core and B e antigens in chronic hepatitis B. J Med Virol (1990) 1.11
Placental alkaline phosphatase, alphafetoprotein and carcinoembryonic antigen in testicular tumors. Tissue typing by means of cytologic smears. Int J Cancer (1979) 1.11
Antigenic diversity of hepatitis B virus strains of genotype F in Amerindians and other population groups from Venezuela. J Clin Microbiol (1998) 1.10
Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides. J Virol (1989) 1.10
Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob Agents Chemother (1988) 1.10
The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline. Antiviral Res (1991) 1.10
Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies. Immunology (1991) 1.09
Detection of e antigen and antibody: correlations with hapatitis B surface and hepatitis B core antigens, liver disease, and outcome in hepatitis B infections. Gastroenterology (1976) 1.09
Antibodies to various herpesviruses in sera from patients with sarcoidosis. J Natl Cancer Inst (1971) 1.08
Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation (1984) 1.08
Bone marrow colony-stimulating activity of sera in infectious mononucleosis. Br Med J (1968) 1.08
Structural studies of the Klebsiella O group 8 lipopolysaccharide. Acta Chem Scand (1973) 1.08
Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. J Clin Virol (1999) 1.08
Increased levels of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol (1994) 1.07
Genetic relatedness of Sindbis virus strains from Europe, Middle East, and Africa. Virology (1996) 1.06
Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl (1985) 1.05
Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.05
Presumed common source outbreaks of hepatitis A in an endemic area confirmed by limited sequencing within the VP1 region. J Med Virol (2001) 1.05
Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification of internal and surface-exposed sequences. J Gen Virol (1993) 1.04
Molecular basis for serological cross-reactivity between enteroviruses. Clin Diagn Lab Immunol (1994) 1.04
Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr (1991) 1.04
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis (1998) 1.04
Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. Vaccine (2001) 1.03
Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine. Eur J Immunol (1997) 1.02
Epitope mapping of the HIV-1 gag region with monoclonal antibodies. Mol Immunol (1990) 1.02